Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension
https://doi.org/10.15829/1560-4071-2018-12-131-142
About the Authors
Zh. D. KobalavaRussian Federation
A. O. Konradi
Russian Federation
S. V. Nedogoda
Russian Federation
G. P. Arutyunov
Russian Federation
E. I. Baranova
Russian Federation
O. L. Barbarash
Russian Federation
S. V. Villevalde
Russian Federation
A. S. Galyavich
Russian Federation
M. G. Glezer
Russian Federation
O. M. Drapkina
Russian Federation
Yu. V. Kotovskaya
Russian Federation
R. A. Libis
Russian Federation
Yu. M. Lopatin
Russian Federation
A. O. Nedoshivin
Russian Federation
O. D. Ostroumova
Russian Federation
L. G. Ratova
O. N. Tkacheva
Russian Federation
I. E. Chazova
Russian Federation
A. I. Chesnikova
Russian Federation
G. A. Chumakova
Russian Federation
References
1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013;34:2159-219. doi:10.1097/HJH.0b013e328364ca4c.
3. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens. 2014;32:2285-95.
4. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure — meta-analyses of randomized trials. J Hypertens. 2016;34:373-84.
5. Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184-91.
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J Hypertens. 2014;32:2296304.
7. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43.
8. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67.
9. Bundy JD, Li C, Stuchlik P, et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis. JAMA Cardiol. 2017;2(7):775-81. doi:10.1001/jamacardio.2017.1421.
10. Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and metaanalysis. JAMA Intern Med. 2018;178:28-36.
11. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:1321-41.
12. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events — meta-analyses of randomized trials. J Hypertens. 2016;34:1451-63.
13. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34:1921-32.
14. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324. doi:10.1161/HYP.0000000000000066. Epub 2017 Nov 13.
15. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729-41.
16. Kojima S, Matsui K, Ogawa H. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017;69(1):169-75. doi:10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20.
17. Baber RJ, Panay N&A. Fenton the IMS Writing Group (2016) 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 19:2, 109-50, doi:10.3109/13697137.2015.1129166.
18. Wellons M, Ouyang P, Schreiner P, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause: The Journal of The North American Menopause Society. 2012;19(10):1081-7. doi:10.1097/gme.0b013e3182517bd0.
19. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality. JAMA Cardiol. 2016; doi:10.1001/jamacardio.2016.2415.
20. Wright JT Jr, Williamson JD, Whelton PK, et al. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-116.
21. Yusuf S, Lonn E, Pais P. HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032-43.
22. Julius S, Nesbitt SD, Egan BM, et al. for the Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97.
23. Lüders S, Schrader J, Berger J. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487-96. doi:10.1097/HJH.0b013e3282ff8864.
24. Fuchs FD, Fuchs SC, Poli-de-Figueiredo CE, et al. Effectiveness of low-dose diuretics for blood pressure reduction to optimal values in prehypertension: a randomized clinical trial. J Hypertens. 2018;36(4):933-8. doi:10.1097/HJH.0000000000001624.
25. Bohm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226-37.
26. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25:83-92.
27. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different ontreatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-64.
28. Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2018;71(5):848-57. doi:10.1161/HYPERTENSIONAHA.117.10479.
29. Polese A, De Cesare N, Montorsi P, et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation.1991;83:845-53.
30. Vidal-Petiot E, Ford I, Greenlaw N, et al. CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388:2142-52.
31. Fang J, Madhavan S, Cohen H, et al. Isolated diastolic hypertension. A favorable finding among young and middle-aged hypertensive subjects. Hypertension. 1995;26(3):377-82.
32. Strandberg TE, Salomaa VV, Vanhanen HT, et al. Isolated diastolic hypertension, pulse pressure, and mean arterial pressure as predictors of mortality during a follow-up of up to 32 years. J Hypertens. 2002;20(3):399-404.
33. Hozawa A, Ohkubo T, Nagai K, et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasamastudy. Arch Intern Med. 2000;160(21):3301-6.
34. Petrovitch H, Curb JD, Bloom-Marcus E. Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke. 1995;26(1):25-9.
35. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37:1933-40.
36. Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5:131-40.
37. Corrao G, Parodi A, Nicotra F, et al. Better Compliance to Antihypertensive Medications Reduces Cardiovascular Risk. Journal of Hypertension. 2011;29:610-8. doi:10.1097/HJH.0b013e328342ca97.
38. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group and Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl. 2012;2:337-414.
39. Guidelines Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology. 2017;33:557-76.
40. Chobanian AV. Hypertension in 2017 — What Is the Right Target? JAMA. 2017;317(6):579-80.
41. Williamson JD, Supiano MA, Applegate WB. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673-82.
42. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 — benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and metaregression analyses of randomized trials. J Hypertens. 2018;36(8):1622-36. doi:10.1097/HJH.0000000000001787.
43. Tkacheva ON, Runikhina NK, Ostapenko VS, et al. Validation of the senile asthenia syndrome questionnaire in outpatient practice. Uspekhi Gerontologii. 2017;2:236-42. (In Russ.)
44. Benetos A, Bulpitt CJ, Petrovic M, et al. An expert opinion from the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the management of hypertension in very old, frail subjects. Hypertension. 2016;67:820-5. doi:10.1161/HYPERTENSIONAHA.115.07020.
45. Forman DE, Arena R, Boxer R, et al. American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Prioritizing Functional Capacity as a Principal End Point for Therapies Oriented to Older Adults With Cardiovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017 Apr 18;135(16):e894-e918. doi:10.1161/CIR.0000000000000483.
46. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014; 45.
Review
For citations:
Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Villevalde S.V., Galyavich A.S., Glezer M.G., Drapkina O.M., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Nedoshivin A.O., Ostroumova O.D., Ratova L.G., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):131-142. (In Russ.) https://doi.org/10.15829/1560-4071-2018-12-131-142